RET fusion

P3, N=223, Terminated, Hoffmann-La Roche | Completed --> Terminated; Early termination of the study resulted from organizational and commercial decisions that led to the discontinuation of pralsetinib's global marketing and development in all territories (excluding US and Greater China).

P2, N=56, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

One patient with acquired fusion gene mutations developed small-cell lung cancer transformation after ALK-TKIs resistance. Key Words: Lung cancer, ALK fusion, RET fusion, ROS1 fusion, EGFR-TKIs-resistance, Targeted therapy.

iza-bren demonstrated encouraging antitumor activity and a manageable safety profile in pretreated NSCLC patients with diverse GAs outside of classical EGFR mutations, especially in EGFR exon20ins/nonclassical and HER2 mutations.

Success in this arena will hinge on utilitarian biomarker-based cohort selection, the discovery of fresh immunogenic epitopes, and the meticulous design of synergistic treatment combinations. The synergistic leverage of genomic, transcriptomic, and immune landscape dissection, coupled with cutting-edge engineered lymphocyte platforms and engineered oncolytic vectors, may finally position immunotherapy as an unassailable pillar of bespoke medicine for advanced thyroid carcinomas.

One case showed an NOL10::ALK out-of-frame fusion with negative ALK immunohistochemistry and equivocal ALK FISH results. Because the expression imbalance method can detect novel fusions, we recommend its implementation with confirmation testing.

P=N/A, N=94, Recruiting, Zhejiang Provincial People's Hospital | Not yet recruiting --> Recruiting | N=55 --> 94

F1CDx recommended FDA-approved therapies relevant to the tumor type in 41.7% of cases and tumor-agnostic or off-label therapies in 50.4%. Conclusions F1CDx profiling identified a broad spectrum of actionable alterations across diverse tumors, highlighting its strong potential to expand therapeutic options and advance precision oncology in real-world Indian practice.

Furthermore, the review elaborates on the clinical efficacy of highly selective RET inhibitors (selpercatinib and pralsetinib), including their breakthroughs in pediatric patients and radioactive iodine-refractory cases. Primary and acquired resistance mechanisms (on-target mutations, bypass activation) and corresponding strategies (next-generation inhibitors, combination therapies) are also analyzed. By integrating recent advances in basic and clinical research, this review provides a comprehensive reference for the precision diagnosis and treatment, mechanistic investigation, and drug development for RET fusion-positive PTC.

P=N/A, N=25, Not yet recruiting, Fudan University

RET fusion-positive LUAD comprises biologically heterogeneous subsets defined by fusion partners. KIF5B-RET tend to occur at earlier stages, whereas non-KIF5B are more frequently associated with CDKN2A co-mutations and may derive greater benefit from selective RET inhibition. Immunochemotherapy demonstrates comparable efficacy regardless of fusion partner, highlighting the need for partner-specific therapeutic strategies in RET fusion-positive LUAD.

P2, N=61, Not yet recruiting, Guangdong Association of Clinical Trials